PDB Short entry for 1AJ6 HEADER TOPOISOMERASE 15-MAY-97 1AJ6 TITLE NOVOBIOCIN-RESISTANT MUTANT (R136H) OF THE N-TERMINAL 24 KDA FRAGMENT TITLE 2 OF DNA GYRASE B COMPLEXED WITH NOVOBIOCIN AT 2.3 ANGSTROMS RESOLUTION COMPND MOL_ID: 1; COMPND 2 MOLECULE: GYRASE; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: N-TERMINAL 24 KDA; COMPND 5 EC: 5.99.1.3; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: ESCHERICHIA COLI; SOURCE 3 ORGANISM_TAXID: 562; SOURCE 4 CELLULAR_LOCATION: CYTOPLASM; SOURCE 5 GENE: GYRB; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: MM294; SOURCE 9 EXPRESSION_SYSTEM_CELLULAR_LOCATION: CYTOPLASM; SOURCE 10 OTHER_DETAILS: PLASMID PTB382 ENCODING MUTANT DERIVED FROM PAM24 SOURCE 11 WHICH ENCODES 24 KDA SUBDOMAIN (SUPPLIED BY A. MAXWELL, LEICESTER), SOURCE 12 WHICH IN TURN WAS DERIVED FROM PAG111 PLASMID WHICH ENCODES FOR GYRB KEYWDS TOPOISOMERASE, GYRASE, NOVOBIOCIN, ANTIBIOTIC, RESISTANT MUTANT EXPDTA X-RAY DIFFRACTION AUTHOR S.A.WESTON,A.TUNNICLIFFE,R.A.PAUPTIT REVDAT 6 03-APR-24 1AJ6 1 REMARK REVDAT 5 07-FEB-24 1AJ6 1 REMARK REVDAT 4 03-NOV-21 1AJ6 1 REMARK SEQADV REVDAT 3 13-JUL-11 1AJ6 1 VERSN REVDAT 2 24-FEB-09 1AJ6 1 VERSN REVDAT 1 20-MAY-98 1AJ6 0 JRNL AUTH G.A.HOLDGATE,A.TUNNICLIFFE,W.H.WARD,S.A.WESTON,G.ROSENBROCK, JRNL AUTH 2 P.T.BARTH,I.W.TAYLOR,R.A.PAUPTIT,D.TIMMS JRNL TITL THE ENTROPIC PENALTY OF ORDERED WATER ACCOUNTS FOR WEAKER JRNL TITL 2 BINDING OF THE ANTIBIOTIC NOVOBIOCIN TO A RESISTANT MUTANT JRNL TITL 3 OF DNA GYRASE: A THERMODYNAMIC AND CRYSTALLOGRAPHIC STUDY. JRNL REF BIOCHEMISTRY V. 36 9663 1997 JRNL REFN ISSN 0006-2960 JRNL PMID 9245398 JRNL DOI 10.1021/BI970294+ REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH R.A.PAUPTIT,S.A.WESTON,A.L.BREEZE,D.J.DERBYSHIRE,A.D.TUCKER, REMARK 1 AUTH 2 N.HALES,D.HOLLINSHEAD,D.TIMMS REMARK 1 TITL ANTIBACTERIAL DESIGN BASED ON THE STRUCTURES OF REMARK 1 TITL 2 GYRASE-INHIBITOR COMPLEXES REMARK 1 REF TO BE PUBLISHED REMARK 1 REFN REMARK 1 REFERENCE 2 REMARK 1 AUTH F.T.TSAI,O.M.SINGH,T.SKARZYNSKI,A.J.WONACOTT,S.WESTON, REMARK 1 AUTH 2 A.TUCKER,R.A.PAUPTIT,A.L.BREEZE,J.P.POYSER,R.O'BRIEN, REMARK 1 AUTH 3 J.E.LADBURY,D.B.WIGLEY REMARK 1 TITL THE HIGH-RESOLUTION CRYSTAL STRUCTURE OF A 24-KDA GYRASE B REMARK 1 TITL 2 FRAGMENT FROM E. COLI COMPLEXED WITH ONE OF THE MOST POTENT REMARK 1 TITL 3 COUMARIN INHIBITORS, CLOROBIOCIN REMARK 1 REF PROTEINS V. 28 41 1997 REMARK 1 REFN ISSN 0887-3585 REMARK 1 REFERENCE 3 REMARK 1 AUTH R.J.LEWIS,O.M.SINGH,C.V.SMITH,T.SKARZYNSKI,A.MAXWELL, REMARK 1 AUTH 2 A.J.WONACOTT,D.B.WIGLEY REMARK 1 TITL THE NATURE OF INHIBITION OF DNA GYRASE BY THE COUMARINS AND REMARK 1 TITL 2 THE CYCLOTHIALIDINES REVEALED BY X-RAY CRYSTALLOGRAPHY REMARK 1 REF EMBO J. V. 15 1412 1996 REMARK 1 REFN ISSN 0261-4189 REMARK 2 REMARK 2 RESOLUTION. 2.30 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : TNT 5D REMARK 3 AUTHORS : TRONRUD,TEN EYCK,MATTHEWS REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.30 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 19.80 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 95.0 REMARK 3 NUMBER OF REFLECTIONS : 9455 REMARK 3 REMARK 3 USING DATA ABOVE SIGMA CUTOFF. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.206 REMARK 3 R VALUE (WORKING SET) : 0.195 REMARK 3 FREE R VALUE : 0.290 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.000 REMARK 3 FREE R VALUE TEST SET COUNT : 999 REMARK 3 REMARK 3 USING ALL DATA, NO SIGMA CUTOFF. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2060 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.1970 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.299 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 10.00 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 999 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 9455 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1459 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 44 REMARK 3 SOLVENT ATOMS : 89 REMARK 3 REMARK 3 WILSON B VALUE (FROM FCALC, A**2) : 23.700 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. RMS WEIGHT COUNT REMARK 3 BOND LENGTHS (A) : 0.012 ; 3.000 ; 1531 REMARK 3 BOND ANGLES (DEGREES) : 1.366 ; 3.000 ; 2076 REMARK 3 TORSION ANGLES (DEGREES) : 18.900; 0.000 ; 886 REMARK 3 PSEUDOROTATION ANGLES (DEGREES) : NULL ; NULL ; NULL REMARK 3 TRIGONAL CARBON PLANES (A) : 0.010 ; 5.000 ; 32 REMARK 3 GENERAL PLANES (A) : 0.015 ; 10.000; 228 REMARK 3 ISOTROPIC THERMAL FACTORS (A**2) : 2.100 ; 20.000; 1521 REMARK 3 NON-BONDED CONTACTS (A) : 0.051 ; 8.000 ; 32 REMARK 3 REMARK 3 INCORRECT CHIRAL-CENTERS (COUNT) : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : TNT REMARK 3 KSOL : 1.00 REMARK 3 BSOL : 241.0 REMARK 3 REMARK 3 RESTRAINT LIBRARIES. REMARK 3 STEREOCHEMISTRY : TNT PROGEO REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS : TNT BCORREL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REMARK 3 STRAINED GEOMETRY AND DIFFERENCE DENSITY AT PRO 23 SUGGEST REMARK 3 IT MIGHT HAVE MORE THAN ONE CONFORMATION. REMARK 3 REMARK 3 ASN 178 IS IN A DISALLOWED REGION OF THE RAMACHANDRAN PLOT. REMARK 3 IT ADOPTS A CLASSICAL C-7 AXIAL CONFORMATION TYPICAL OF REMARK 3 GLYCINE RESIDUES WITH A CO(N-1)..N(N+1) H-BOND. REMARK 4 REMARK 4 1AJ6 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000170881. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : JUN-96 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SRS REMARK 200 BEAMLINE : PX9.6 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.87 REMARK 200 MONOCHROMATOR : SI(111) REMARK 200 OPTICS : VERTICALLY FOCUSSED PT-COATED REMARK 200 MIRROR REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : CCP4 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 9455 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.300 REMARK 200 RESOLUTION RANGE LOW (A) : 19.800 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.8 REMARK 200 DATA REDUNDANCY : 5.100 REMARK 200 R MERGE (I) : 0.06500 REMARK 200 R SYM (I) : 0.06500 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 8.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.30 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.38 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.0 REMARK 200 DATA REDUNDANCY IN SHELL : 5.20 REMARK 200 R MERGE FOR SHELL (I) : 0.13100 REMARK 200 R SYM FOR SHELL (I) : 0.13100 REMARK 200 <I/SIGMA(I)> FOR SHELL : 5.600 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: DIFFERENCE FOURIER REMARK 200 SOFTWARE USED: CCP4 REMARK 200 STARTING MODEL: WILD-TYPE 24KDA FRAGMENT/NOVOBIOCIN COMPLEX REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 45.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.20 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: HANGING DROP VAPOR DIFFUSION; 12MGS/ML REMARK 280 PROTEIN/NOVOBIOCIN MIXED WITH EQUAL VOLUME OF RESERVOIR SOLUTION REMARK 280 (12% V/V PEG200, 100MM MES PH6.2), VAPOR DIFFUSION - HANGING REMARK 280 DROP, VAPOR DIFFUSION, HANGING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 19.75000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 57.20500 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 23.86000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 57.20500 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 19.75000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 23.86000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 THE MUTATED RESIDUE HIS 136 HAS AN UNUSUAL ECLIPSED SIDE REMARK 400 CHAIN CONFORMATION WHICH IS STABILISED BY HYDROGEN BONDS. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER A 2 REMARK 465 ASN A 3 REMARK 465 SER A 4 REMARK 465 TYR A 5 REMARK 465 ASP A 6 REMARK 465 SER A 7 REMARK 465 SER A 8 REMARK 465 SER A 9 REMARK 465 ILE A 10 REMARK 465 LYS A 11 REMARK 465 HIS A 83 REMARK 465 PRO A 84 REMARK 465 GLU A 85 REMARK 465 GLU A 86 REMARK 465 GLY A 87 REMARK 465 ASP A 105 REMARK 465 ASP A 106 REMARK 465 ASN A 107 REMARK 465 SER A 108 REMARK 465 TYR A 109 REMARK 465 LYS A 110 REMARK 465 VAL A 111 REMARK 465 TYR A 218 REMARK 465 GLU A 219 REMARK 465 GLY A 220 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 14 CG CD CE NZ REMARK 470 ASP A 49 CG OD1 OD2 REMARK 470 LYS A 57 CD CE NZ REMARK 470 LYS A 103 CG CD CE NZ REMARK 470 GLN A 128 CG CD OE1 NE2 REMARK 470 GLU A 159 CG CD OE1 OE2 REMARK 470 LYS A 162 CD CE NZ REMARK 470 GLU A 181 CD OE1 OE2 REMARK 470 LYS A 208 CD CE NZ REMARK 470 GLU A 213 CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 PRO A 23 C - N - CD ANGL. DEV. = -16.0 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 HIS A 99 50.84 34.57 REMARK 500 HIS A 136 154.97 177.56 REMARK 500 ASN A 178 -83.09 72.85 REMARK 500 ASP A 210 1.32 -150.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NOV A 1 DBREF 1AJ6 A 2 220 UNP P06982 GYRB_ECOLI 1 219 SEQADV 1AJ6 HIS A 136 UNP P06982 ARG 135 ENGINEERED MUTATION SEQRES 1 A 219 SER ASN SER TYR ASP SER SER SER ILE LYS VAL LEU LYS SEQRES 2 A 219 GLY LEU ASP ALA VAL ARG LYS ARG PRO GLY MET TYR ILE SEQRES 3 A 219 GLY ASP THR ASP ASP GLY THR GLY LEU HIS HIS MET VAL SEQRES 4 A 219 PHE GLU VAL VAL ASP ASN ALA ILE ASP GLU ALA LEU ALA SEQRES 5 A 219 GLY HIS CYS LYS GLU ILE ILE VAL THR ILE HIS ALA ASP SEQRES 6 A 219 ASN SER VAL SER VAL GLN ASP ASP GLY ARG GLY ILE PRO SEQRES 7 A 219 THR GLY ILE HIS PRO GLU GLU GLY VAL SER ALA ALA GLU SEQRES 8 A 219 VAL ILE MET THR VAL LEU HIS ALA GLY GLY LYS PHE ASP SEQRES 9 A 219 ASP ASN SER TYR LYS VAL SER GLY GLY LEU HIS GLY VAL SEQRES 10 A 219 GLY VAL SER VAL VAL ASN ALA LEU SER GLN LYS LEU GLU SEQRES 11 A 219 LEU VAL ILE GLN HIS GLU GLY LYS ILE HIS ARG GLN ILE SEQRES 12 A 219 TYR GLU HIS GLY VAL PRO GLN ALA PRO LEU ALA VAL THR SEQRES 13 A 219 GLY GLU THR GLU LYS THR GLY THR MET VAL ARG PHE TRP SEQRES 14 A 219 PRO SER LEU GLU THR PHE THR ASN VAL THR GLU PHE GLU SEQRES 15 A 219 TYR GLU ILE LEU ALA LYS ARG LEU ARG GLU LEU SER PHE SEQRES 16 A 219 LEU ASN SER GLY VAL SER ILE ARG LEU ARG ASP LYS ARG SEQRES 17 A 219 ASP GLY LYS GLU ASP HIS PHE HIS TYR GLU GLY HET NOV A 1 44 HETNAM NOV NOVOBIOCIN HETSYN NOV 4-HYDROXY-3-[4-HYDROXY-3-(3-METHYLBUT-2-ENYL) HETSYN 2 NOV BENZAMIDO]-8-METHYLCOUMARIN-7-YL 3-O-CARBAMOYL-5,5-DI- HETSYN 3 NOV C-METHYL-ALPHA-L-LYXOFURANOSIDE FORMUL 2 NOV C31 H36 N2 O11 FORMUL 3 HOH *89(H2 O) HELIX 1 1 LEU A 13 LYS A 21 1 9 HELIX 2 2 PRO A 23 ILE A 27 1 5 HELIX 3 3 THR A 34 LEU A 52 1 19 HELIX 4 4 ALA A 90 THR A 96 1 7 HELIX 5 5 VAL A 120 ALA A 125 1 6 HELIX 6 6 TYR A 184 ASN A 198 1 15 SHEET 1 A 8 GLY A 211 PHE A 216 0 SHEET 2 A 8 ILE A 203 LYS A 208 -1 N LEU A 205 O ASP A 214 SHEET 3 A 8 ILE A 59 HIS A 64 1 N ILE A 59 O ARG A 204 SHEET 4 A 8 SER A 68 ASP A 73 -1 N GLN A 72 O ILE A 60 SHEET 5 A 8 GLY A 164 PRO A 171 -1 N PHE A 169 O VAL A 69 SHEET 6 A 8 SER A 127 HIS A 136 -1 N GLN A 135 O GLY A 164 SHEET 7 A 8 LYS A 139 TYR A 145 -1 N TYR A 145 O LEU A 130 SHEET 8 A 8 ALA A 155 GLU A 159 -1 N ALA A 155 O ARG A 142 SITE 1 AC1 10 ASN A 46 GLU A 50 ASP A 73 ARG A 76 SITE 2 AC1 10 ILE A 78 PRO A 79 HOH A 227 HOH A 231 SITE 3 AC1 10 HOH A 265 HOH A 270 CRYST1 39.500 47.720 114.410 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.025316 0.000000 0.000000 0.00000 SCALE2 0.000000 0.020956 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008740 0.00000